[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582735":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":31,"centralContacts":36,"locations":43,"responsibleParty":62,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":10,"enrollmentInfo":77,"targetDuration":10,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Carol Davila University of Medicine and Pharmacy","OTHER",[8,15,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Pancreatic cyst",null,"Neoplastic pancreatic cystic lesion",[13,14],"Diagnostic Test: computerized tomography","Diagnostic Test: Endosonography (EUS)",{"label":16,"type":10,"description":17,"interventionNames":10},"PDAC","Pancreatic ductal adenocarcinoma for supplementary analysis",{"label":19,"type":10,"description":20,"interventionNames":10},"Control group","Control group for comparison",[22,27],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"DIAGNOSTIC_TEST","computerized tomography","Little is known about the prevalence of pancreatic steatosis in patients with pancreatic cystic lesions therefore this observational study aims to clarify the data.",[9],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Endosonography (EUS)","EUS can better evaluate all pancreatic cysts, therefore is mandatory in this observational study.",[9],[32],{"name":33,"affiliation":34,"role":35},"Mihai Ciocirlan, MD PhD","Romanian Society of Digestive Endoscopy","STUDY_CHAIR",[37],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Catalina Vladut, MD PhD","CONTACT","+40751015445","40","drcatalinavladut@gmail.com",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Prof Dr Agrippa Ionescu; Clinical Emergency Hospital","RECRUITING","Bucharest","Sector 1","011356","Romania","RO",{"type":53,"coordinates":54},"Point",[55,56],26.10626,44.43225,{"lat":56,"lon":55},[59],{"name":60,"role":39,"phone":10,"phoneExt":10,"email":61},"Mihai Ciocirlan, MD","ciocirlan@hey.com",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Vladut Catalina","Principal Investigator, Gastroenterologist, Assistant Lecturer University of Medicine and Pharmacy","100582735","prevalence-of-pancreatic-steatosis-in-pancreatic-cystic-neoplasms-and-pancreatic-adenocarcinoma-100582735",false,"NCT06867172","Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma","The Emerging Issue - Pancreatic Steatosis Prevalence in Pancreatic Cystic Neoplasms and Adenocarcinoma: Insights From a Single-center Retrospective Study","SPACE","Inclusion Criteria:\n\n* Age 18 or older\n* Patients with at least 1 pancreatic cystic lesion based on CT and EUS features, with a cyst size ≥ 5mm; or healthy subjects or PDAC (confirmed by histopathological exam).\n\nExclusion Criteria:\n\n* No evidence of written informed consent\n* Patients with contraindications for endoscopy due to comorbidities\n* Metal stent in hepato-bilio-pancreatic region at time of baseline CT-imaging (vascular, luminal and biliary)\n* Acute pancreatitis at baseline imaging\n* Pancreatic surgery at baseline imaging in our department\n* Splenectomy\n* Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women",true,"ALL","18 Years",{"count":78,"type":79},66,"ESTIMATED","OBSERVATIONAL","Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS).\n\nThe primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk.\n\nThe secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.",[83,84,85],"Pancreatic Steatosis","Pancreatic Cyst","Pancreatic Adenocarcinoma",[87,88,89,90,91,92],"pancreas","steatosis","cyst","cancer","adenocarcinoma","fat","2025-03-06",{"date":95,"type":96},"2025-03-10","ACTUAL",{"date":98,"type":96},"2019-01-01",{"date":100,"type":79},"2025-06-30",{"name":5,"class":6},1]